Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Intra-articular injection of allogeneic canine adipose-derived stem cell enriched secretome in dogs undergoing tibial plateau leveling osteotomy: a prospective double-blind and randomized pilot trial.

Carrera ALC., Minto BW., Alcântara BM., Previtali DAC., Faustino RCS., Tavares ABL.

Randomized Controlled Trial with a reported sample of 10 on Osteoarthritis, Ligament Injury, published in Vet Res Commun (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Vet Res Commun (2026)
Country
Switzerland
Reported sample size
10
Source database
PubMed
PMID
42287504
PMCID
PMC13264577
DOI
10.1007/s11259-026-11343-9

Abstract (original English)

This pilot study evaluated the short- and mid-term outcomes of intra-articular allogeneic canine adipose-derived stem cell (ADSC) enriched secretome in dogs undergoing tibial plateau levelling osteotomy (TPLO), focusing on postsurgical recovery and osteoarthritis (OA) progression. Twenty client-owned dogs were randomly assigned (n = 10 per group) to a control group (CG), receiving placebo, or a treated group (ADSC-Se), receiving 250 µg of ADSC-derived enriched secretome intra-articularly at the end of TPLO. Lameness, stifle pain, accelerometry, and OA-related changes assessed by radiography and articular ultrasonography scores were evaluated for up to 150 days postoperatively. Median lameness (3 to 1) and stifle pain (2 to 0) scores decreased in ADSC-Se group at 15 days postoperatively, whereas similar improvements in CG occurred later (60 and 90 days postoperatively, respectively). No differences occurred in accelerometry outcomes. Radiographic assessment showed progressive median OA in the CG (1 to 2), whereas OA scores decreased in ADSC-Se group (1 to 0) from 15 days postoperatively and remained stable thereafter. Ultrasonography revealed reduced median joint effusion scores in ADSC-Se group (1 to 0) from 30 days postoperatively, with improvement in cartilage appearance from thin to normal, whereas CG showed no effusion improvement and cartilage deterioration. Radiographic b

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsDogsFemaleMaleAdipose TissueDog DiseasesDouble-Blind MethodInjections, Intra-ArticularLameness, AnimalOsteoarthritis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research